ACCESS Newswire

Nomads

9.5.2023 12:31:45 CEST | ACCESS Newswire | Press release

Share
HOYA Vision Care Launches MiYOSMART Sun Spectacle Lenses Combining Protection From Intense Sunlight With Myopia Management

BANGKOK / ACCESSWIRE / May 9, 2023 / HOYA Vision Care, a leader in optical technology innovation, continues to roll out the MiYOSMART sun range, with a planned reach of 30 countries, over the next few months following the soft launch in April 2023. The photochromic spectacle lenses, MiYOSMART Chameleon, and polarised spectacle lenses, MiYOSMART Sunbird, were developed to slow down myopia progression in children using D.I.M.S. Technology while providing protection from intense sunlight.[1-5] These two new products, along with the MiYOSMART clear spectacle lenses which launched in 2018, give children the freedom to comfortably take part in the activities they enjoy indoors and outdoors without compromising their eyesight.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
MiYOSMART Sun Spectacle Lenses
Sun protection for children

MiYOSMART Chameleon and MiYOSMART Sunbird both provide protection from intense sunlight while simultaneously correcting the myopic refractive error and slowing myopia progression.[1-5] The new spectacle lenses utilise the same D.I.M.S. Technology used in the award-winning [6,7] and noninvasive MiYOSMART clear spectacle lenses, shown to slow myopia progression by 60% in children aged 8 to 13.[3] Due to its HOYA photochromic lens technology, MiYOSMART Chameleon is an all-in-one solution to myopia management and protected outdoor activity. It rapidly adapts to the level of sunlight and fades back to clear indoors in seconds.[8] Meanwhile, MiYOSMART Sunbird is the ideal addition to MiYOSMART clear spectacle lenses for extra protection from intense sunlight and glare.[1,9,10] It also offers vibrant colours and rich contrast in bright light, allowing children to fully experience the beauty of outdoors.[11]

"Children's vision is worth protecting. By acting today, we give them more opportunity tomorrow," said Frederiek Ysebaert, Managing Director of the Pediatric Care Business Unit at HOYA Vision Care. "With the launch of MiYOSMART sun spectacle lenses, inspired by our discussions with eye care professionals, we can enable children across the world to spend more time outdoors while protecting their eyes from intense sunlight, maximising the benefits of D.I.M.S. Technology on myopia progression."

Alongside the launch of the MiYOSMART sun range, HOYA Vision Care will launch "protect how they see the world," a dedicated global campaign to raise awareness of the importance of outdoor time and sun protection in children. Spending time outdoors may slow down myopia progression in children[6,7], and as such it is the most common recommended behavioural management for myopia given by eye care professionals.[8] However, as the majority of lifetime sun exposure occurs under the age of 21, it is necessary to prevent long-term eye damage to children's eyes with effective and reliable sun protection.[1,9] This is particularly important for myopic children using atropine eyedrops for myopia management, and those that are light-sensitive.[2,10,11]

From the launch in 2018 until the end of 2022, over four million MiYOSMART spectacle lenses were purchased by parents across the world.[18] With the launch of MiYOSMART Chameleon and MiYOSMART Sunbird, HOYA Vision Care will continue to help fight and control the growing problem of myopia around the world.

Product Disclaimer: MiYOSMART spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.

About HOYA Vision Care

For over 60 years, HOYA Vision Care has been a passionate and global leader in optical technology innovation. As a manufacturer of high-quality, high-performing eyeglass lenses, HOYA continuously aims to bring the best possible vision care solutions to eye care professionals and their patients around the world. The company supplies lenses in 110 countries with a network of over 17,000 employees and 43 laboratories around the globe.

References

1. WSPOS. Sunlight Exposure & Children's Eyes Consensus Statement. 2016. Available at: https://www.wspos.org/wspos-sunlight-exposure-childrens-eyes-consensus-statement/ (Last accessed 28/03/2023)

2. Wu PC, Chuang MN, Choi J, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond). 2019;33(1):3-13.

3. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-368.

4. Lakkis C, Weidemann K. Evaluation of the performance of photochromic spectacle lenses in children and adolescents aged 10 to 15 years. Clin Exp Optom. 2006;89(4):246-252. .

5. Renzi-Hammond LM, Hammond BR Jr. The effects of photochromic lenses on visual performance. Clin Exp Optom. 2016;99(6):568-574.

6. Winners of the exhibition's grand prix. Inventions Geneva. N.D. Available from: https://inventions-geneva.ch/en/winners/ (Last accessed 28/03/2023)

7. Winners 2020. Silmo Paris. 2020. https://en.silmoparis.com/SILMO-d-OR/SILMO-dOrAwards/2020-Winners# (Last accessed 28/03/2023).

8. Hoya data on file. HOYA Internal Product Performance Validation. 09/2022

9. Hoya data on file. UVA and UVB transmittance for MiYOSMART photochromic and polarized sun spectacle lenses. 07/2022

10. Hoya data on file. Luminous transmittance for MiYOSMART polarized sun spectacle lenses. 07/2022

11. Quintana MS, Langa A, del Moral-Martinez I, et al. Polarized Filters Enhance Contrast Sensitivity When Glare Is Produced On A Flat Surface Under Photopic Conditions. Invest Ophthalmol Vis Sci. 2006;47(13):1225.

12. Ho CL, Wu WF, Liou YM. Dose-Response Relationship of Outdoor Exposure and Myopia Indicators: A Systematic Review and Meta-Analysis of Various Research Methods. Int J Environ Res Public Health. 2019;16(14):2595.

13. Jonas JB, Ang M, Cho P, et al. IMI prevention of myopia and its progression. Invest Ophthalmol Vis Sci. 2021;62(5):6.

14. WSPOS. Myopia Survey Data. November 2022. Presented as part of WSPOS Symposium: Comprehensive Update on Myopia Management.19-20 November 2022. Available from: http://forum.wspos.org/symposium-part-1-comprehensive-update-on-myopia-management-2

15. Prevent Blindness. Children's Eyes are More Susceptible to Long-Term Damage from UV Rays. 2011. Available at: https://preventblindness.org/childrens-eyes-are-more-susceptible-to-longtermdamage-from-uv-rays/ (Last accessed 28/03/2023)

16. Li FF, Yam JC. Low-Concentration Atropine Eye Drops for Myopia Progression. Asia Pac J Ophthalmol (Phila). 2019;8(5):360-365.

17. Gong Q, Janowski M, Luo M, et al. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. JAMA Ophthalmol. 2017;135(6):624-630.

18. Based on number of MiYOSMART lenses sold as per Hoya sales data on file as of December 2022.

Contact Information

Susan Brown
PR Lead
susan@wearenomads.com
8312334616

Related Images

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
MiYOSMART Sun Spectacle Lenses
Sun protection for children
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
HOYA Vision Care
Logo

SOURCE: HOYA Vision Care

To view this piece of content from stats.newswire.com, please give your consent at the top of this page.

View source version on accesswire.com:
https://www.accesswire.com/753658/HOYA-Vision-Care-Launches-MiYOSMART-Sun-Spectacle-Lenses-Combining-Protection-From-Intense-Sunlight-With-Myopia-Management

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release

Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica

Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release

OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to

Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release

CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a

Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in

CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release

TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye